Pathological Complete Response with Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy Followed by Modified Radical Mastectomy in a Patient with HER2-Positive Occult Breast Cancer

Chunchun Chen; Jinhai Zhu; Chao Zhang; Lin Wang; Yulong Li; Mingnan Du

doi:10.12659/AJCR.943936

19 September 2024 : Case report China

Pathological Complete Response with Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy Followed by Modified Radical Mastectomy in a Patient with HER2-Positive Occult Breast Cancer

Challenging differential diagnosis, Unusual or unexpected effect of treatment

Chunchun Chen^1ABCE, Jinhai Zhu^1BCDE*, Chao Zhang^1CDE, Lin Wang^1DE, Yulong Li^1BF, Mingnan Du^1BEF

DOI: 10.12659/AJCR.943936

Am J Case Rep 2024; 25:e943936

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 5. Immunohistochemistry images of (A) human epidermal growth factor receptor 2 (HER2), (B) estrogen receptor (ER), (C) progesterone receptor (PR), and (D) Antigen Kiel 67 (Ki-67) at magnifications of 100×, 200×, and 400× of the core-needle biopsy on February 18, 2022, revealing metastatic invasive carcinoma.

Back to the Article

Pathological Complete Response with Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy Followed by Modified Radical Mastectomy in a Patient with HER2-Positive Occult Breast Cancer

Your Privacy